Testing effectiveness (Phase 2)Study completedNCT01401166
What this trial is testing
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 488